Monteris Medical

Monteris Medical occupies a focused segment of neurosurgical devices: MRI-guided laser interstitial thermal therapy for brain lesions and selected neurological conditions. Its NeuroBlate® System differentiates the company from broader surgical-robotics and medical-device businesses through a brain-specific, minimally invasive approach that combines laser ablation with image guidance and real-time visualization. The available product information describes use in brain tumors, radiation necrosis and epileptic brain tissue, rather than a general-purpose surgical platform. Companies named in the wider neurosurgery and medical-device landscape include Brainlab, Renishaw, Zimmer Biomet, Medtronic, Globus Medical and Accuray; these organizations have broader or differing portfolios, so they should be treated as adjacent market participants rather than interchangeable products. Monteris’s competitive case depends on clinical adoption, procedural outcomes, evidence development and integration into neurosurgical workflows. The company’s reported 787-patient study publication and its March 2026 report on potential interaction between laser ablation and immunotherapy add to its evidence-building activity.

Monteris Medical has developed its brain-focused device business over a long period, having been founded in 1999, and the available employee range is 101–250. Its financing history shows successive development and growth capital: a $26.6 million Series C in 2017, Series D entries of $10.68 million in 2019 and $35 million in 2022, and a $28 million Series E in March 2026. Debt financing has also been a significant part of the capital mix, including $35 million from Trinity Capital on March 12, 2026. The 2026 financing activity is an inflection point in the visible record, with equity and debt announced on the same date and two new investor-affiliated board members identified. Product development is reflected in the reported NeuroBlate NB3 FullFire 1.6 mm probe release, dated May 2024 in the company activity record. Clinical publications, including an August 2026 study involving 787 treated patients, indicate continued effort to build evidence around the platform. The hiring signal is limited to an active careers presence; there is no detailed hiring plan or quantified employee-growth trend available.